Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $28
Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $24
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
ArriVent BioPharma Q3 EPS $(0.81) Beats $(1.05) Estimate, Sales $5.000M
Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30
ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
ArriVent BioPharma (AVBP) Advances ARR 217 Into Phase 1b, Is The Selloff Overdone?
ArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
Why ArriVent BioPharma Stock Is In Focus After Trial Failure And Legal Probe
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
ArriVent BioPharma To Present Initial Safety, Efficacy Results Of Its Phase 1 Trial Of CDH17-Targeted ADC ARR-217 In Participants With Gastrointestinal Cancers At ESMO Congress 2026
B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
ArriVent BioPharma Doses First Patient In Phase 1 Trial Of Dual-Target ADC ARR-002 For Ovarian And Endometrial Cancer
HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27
Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.